Cloud DX Inc.

Cloud DX Inc. operates as a remote patient monitoring company. It offers Cloud DX Connected Health, an end-to-end virtual healthcare platform for monitoring patients with chronic illness, including chronic obstructive pulmonary disease and congestive heart failure, as well as patients recovering from surgery and COVID-19 patients outside hospitals. The company's Cloud DX Connected Health Kits includes its Cloud DX Bluetooth pulse oximeter, the Cloud DX wireless weight scale and optionally, a wireless Bluetooth blood pressure monitor, digital thermometer, and digital wireless glucose meter from 3rd party suppliers. It serves academic institutions, large hospitals, and provincial health authorities in Canada, as well as physician practices and hospitals in the United States. The company also offers VITALITI, a vital sign monitor for measuring electrocardiograph, heart rate, oxygen saturation, respiration, core body temperature, blood pressure, movement, steps, and posture. Cloud DX Inc. is headquartered in Brooklyn, New York.

Cloud DX Inc. trades as CDXFF on OTC. The company is classified in Healthcare / Medical - Healthcare Information Services and reports in USD.

The current profile places the business in Medical - Healthcare Information Services. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $1.81M of revenue and -$10.35M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Cloud DX Inc. can be compared against peers such as Antibe Therapeutics Inc., Bionomics Limited, RIV Capital Inc., Carebook Technologies Inc., CloudMD Software & Services Inc., HealthBeacon plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $9.75M, beta of 0.44, and return on equity of +58.1%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CDXFF currently shows total debt of $14.92M and beta of 0.44. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.clouddx.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.